TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11782895
Drug: Micronized diosmin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized diosmin (Daflon 500 mg)
Study: 2065410
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no patch)
Study: 7073303
Drug: Single-dose trimethoprim-sulphamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose trimethoprim-sulphamethoxazole
Study: 31036580
Drug: Ace‐ER 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ace‐ER 6 g/d
Study: 28527855
Drug: XR-NTX treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-NTX treatment prior to release
Study: 28527855
Drug: Post-release XR-NTX
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-release XR-NTX treatment
Study: 26044070
Drug: bapineuzumab 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: bapineuzumab 0.15 mg/kg
Study: 18985345
Drug: d-amphetamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (0.3 mg/kg i.v.)
Study: 15682684
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO2) treatment (2.8 atmospheres absolute, 100 minutes, three treatments within the first 24 hours)
Study: 8080233
Drug: Mebendazole 500
Normalized name: mebendazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole 500 mg single dose
Study: 2439814
Drug: atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 100 mg
Study: 18391051
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral treatment (CBT)
Study: 30203758
Drug: Lamivudine in
Normalized name: Product containing lamivudine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine in addition to conventional Anti-TB therapy and liver-protecting therapy
Study: 30203758
Drug: Conventional Anti-TB
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Anti-TB therapy and liver-protecting therapy
Study: 24809770
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (nasal saline irrigation + INS)
Study: 12145999
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg
Study: 12145999
Drug: Exemestane 50
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane 50 mg
Study: 12145999
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg (crossover study)
Study: 8679024
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: 50 mg of 0.25% bupivacaine and 100 micrograms of fentanyl
Study: 30677646
Drug: Incongruent medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incongruent medications
Study: 25070148
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of Soli 6 mg plus TOCAS 0.4 mg or Soli 9 mg plus TOCAS 0.4 mg
Study: 20399146
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of imipramine with pseudoephedrine
Study: 9882084
Drug: Dexketoprofen 25
Normalized name: dexketoprofen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen 25 mg
Study: 23360885
Drug: Dexketoprofen 50
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen 50 mg
Study: 8255126
Drug: Dipyrone 2
Normalized name: dipyrone 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 2 g
Study: 7633015
Drug: Clinafloxacin 200
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clinafloxacin 200 mg iv q12h
Study: 7633015
Drug: Theophylline 300
Normalized name: theophylline 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 300 mg tid (initially) then reduced to 200 mg tid after toxicity was observed
Study: 2199211
Drug: Chlorbutol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorbutol (2.5 mg.ml-1)
Study: 2199211
Drug: Methacholine (0.13-4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine (0.13-4.0 mg.ml-1)
Study: 31034594
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (OT) and physical therapy (PT)
Study: 28383379
Drug: pH‐balanced vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH‐balanced vaginal gel containing lactic acid
Study: 28383379
Drug: Placebo (lactate‐free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactate‐free gel)
Study: 19559137
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of peppermint oil
Study: 11501507
Drug: Calcitriol 3
Normalized name: CALCITRIOL 3MCG/GM OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 3 microg g(-1) ointment (Silkis ointment)
Study: 9375952
Drug: Metoprolol CR/XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/XL (12.5 mg or 25 mg once daily, titrated to 200 mg)
Study: 18954355
Drug: 1.23% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.23% sodium fluoride gel administered topically every 24 h for 6 consecutive days
Study: 16176154
Drug: CoQ10 Q-Gel
Normalized name: Q-Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 Q-Gel Softsules
Study: 30185793
Drug: CBD 16
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD 16 mg
Study: 18945240
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone 0.125 mg/kg
Study: 15823446
Drug: Lyso-PAF (L-PAF)
Normalized name: pafuramidine
DrugBank: Pafuramidine (DB06532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyso-PAF (L-PAF) challenge
Study: 1740930
Drug: Unlimited intravenous
Normalized name: MENTHOL 125 mg in 1 mL TOPICAL CREAM [CBD UNLIMITED BALM TOPICAL ANALGESIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unlimited intravenous fluids (1294 +/- 58 ml)
Study: 1740930
Drug: Fluid restriction
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid restriction (500 ml or less, 485 +/- 2 ml)
Study: 6408663
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day amitriptyline (AT)
Study: 29992370
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg beloranib
Study: 28556449
Drug: 1.8 mg
Normalized name: menthol 1.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg beloranib
Study: 25393812
Drug: Independent daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independent daily stress
Study: 25393812
Drug: Dependent daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dependent daily stress
Study: 23290219
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) + basic fibroblast growth factor (bFGF)
Study: 1443508
Drug: Racemic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic ketamine (2 mg/kg)
Study: 1443508
Drug: S(+)‐ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine (1 mg/kg)
Study: 3513810
Drug: Slow-release tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release tablets (5 mg terbutaline sulphate, every 12 h)
Study: 25651782
Drug: Tofacitinib 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 15 mg BID
Study: 15886669
Drug: SIS wound
Normalized name: Oasis Wound Matrix, 3X7cm
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIS wound matrix plus compression therapy (n = 62)
Study: 15886669
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy alone (n = 58)
Study: 19132881
Drug: Nortriptyline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline and Sertraline
Study: 16137089
Drug: Directly loaded
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly loaded Brånemark System or Replace Select Tapered implants (Nobel Biocare AB)
Study: 8538189
Drug: Difluoromethylornithine (DFMO)
Normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Difluoromethylornithine (DFMO) at a dose of 0.25 gm/m2 per day
Study: 7011113
Drug: Reproterol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproterol (20 mg)
Study: 7011113
Drug: Reproterol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproterol (30 mg)
Study: 1415392
Drug: Terbutaline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (5 mg)
Study: 30253043
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid (OCA) 25 mg once daily for 72 weeks
Study: 27137142
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg every 8 hours)
Study: 15322526
Drug: Anti-amyloid strategies
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-amyloid strategies (including secretase inhibition, amyloid-beta aggregation inhibition, immunotherapy)
Study: 11253857
Drug: Prophylactic drug
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic drug therapy
Study: 11253857
Drug: Prophylaxis administered
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis administered selectively to high-risk patients
Study: 9141112
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg budesonide b.i.d. from Aiolos nebulizer
Study: 7114936
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy
Study: 16531708
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant therapy
Study: 30504515
Drug: Nitroglycerin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (200 μg or 300 μg)
Study: 3935343
Drug: Verapamil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (5 mg)
Study: 25458886
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of psyllium and MgSO4 (n=12)
Study: 18786302
Drug: Clopidogrel (600-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600-mg loading dose, 75-mg maintenance dose for 7 days) with ranitidine (150 mg twice daily)
Study: 11942372
Drug: Gadobenate dimeglumine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadobenate dimeglumine, 0.2 mmol/kg bodyweight administered as sequential injections of 0.05, 0.05 and 0.1 mmol/kg over a 20-min period
Study: 11942372
Drug: Gadobenate dimeglumine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadobenate dimeglumine, 0.2 mmol/kg bodyweight administered as sequential injections
Study: 19577405
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment sessions (control)
Study: 18450989
Drug: 0.9 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g/kg dietary protein intake
Study: 18450989
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg dietary protein intake
Study: 30324849
Drug: Combination oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination oxycodone (5‐mg) and acetaminophen (325‐mg) tablets
Study: 25642582
Drug: Behavioral couples
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral couples therapy (BCT-S)
Study: 18837602
Drug: Standard smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard smoking cessation treatment (ST)
Study: 25642582
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (BCT-S and ST)
Study: 25063191
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ) treatment
Study: 18360068
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (5 mg/day of enalapril or imidapril)
Study: 15976965
Drug: Fibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic therapy and intra-aortic balloon counterpulsation (IABP)
Study: 15976965
Drug: Fibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic therapy and intra-aortic balloon counterpulsation (IABP) in patients with Killip class III or IV
Study: 12593493
Drug: Policosanol 10
Normalized name: policosanol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 10 mg once daily
Study: 8752186
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg once daily
Study: 2063598
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 200 mg trapidil daily for 6 weeks
Study: 2063598
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 200 mg pentoxifylline daily for 6 weeks
Study: 28078862
Drug: Proprietary multi‐ingredient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary multi‐ingredient lipid‐lowering supplement (PMILLS)
Study: 23417235
Drug: Booster intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster intervention (brief monthly individual contacts primarily with the children)
Study: 2854781
Drug: Adjuvant intraluminal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant intraluminal 5-FU chemotherapy and intravenous 5-FU chemotherapy (30 mg/kg intraluminally and 10 mg/kg intravenously on the first and second days postoperatively)
Study: 2854781
Drug: Adjuvant intraluminal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant intraluminal 5-FU chemotherapy
Study: 30299412
Drug: Sucrose (SUC;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (SUC; 40 g)
Study: 30299412
Drug: Sodium nitrate
Normalized name: Sodium Nitrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium nitrate (NIT; 800 mg NO3)
Study: 21911051
Drug: Bu‐Fei Yi‐Shen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bu‐Fei Yi‐Shen granule combined with Shu‐Fei Tie acupoint sticking therapy
Study: 21911051
Drug: Oral sustained‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained‐release theophylline and placebo Bu‐Fei Yi‐Shen granule combined with placebo Shu‐Fei Tie acupoint sticking therapy
Study: 15370670
Drug: DTPa-HBV-IPV/Hib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-HBV-IPV/Hib combined vaccine (Group 1)
Study: 9743769
Drug: Portfolio learning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portfolio learning intervention where students followed a patient with cancer for 9 months, supported by bi-monthly small-group tutorials.
Study: 22027699
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg Zx plus 9 mg L
Study: 22027699
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Zx, Zx + L, and L)
Study: 9188761
Drug: Acute hyperglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute hyperglycemia (15 mmol/l)
Study: 2689396
Drug: Cisplatin 40
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40 mg/m2
Study: 2689396
Drug: Cisplatin 20
Normalized name: CISPLATIN 200MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 20 mg/m2
Study: 16042882
Drug: famciclovir 500
Normalized name: famciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famciclovir 500 mg tid
Study: 9841843
Drug: Hib conjugates
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hib conjugates administered to young children (two or three primary doses)
Study: 9841843
Drug: Three primary
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three primary vaccine doses
Study: 2138180
Drug: Topical erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical erythromycin plus zinc
Study: 21360715
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg alone
Study: 7997384
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg alone
Study: 15252707
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine oestrogens plus 2.5 mg medroxyprogesterone acetate
Study: 15790946
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate therapy
Study: 8495532
Drug: Soya milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya milk preparations
Study: 16989497
Drug: Felodipine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5-10 mg)
Study: 2573003
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg Madopar
Study: 21751250
Drug: Duloxetine 60/120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60/120 mg per day for 12 weeks
Study: 9395150
Drug: Paroxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine treatment
Study: 9370180
Drug: Study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group patients with less decrements of serum aluminum (<5.5 microg/L)
Study: 3570859
Drug: Four types
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four types of milk with normal or low lactose and/or fat content, increasing amounts (125, 250, 500, 1000 ml/d)
Study: 3570859
Drug: Increasing amounts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing amounts of milk (125, 250, 500, 1000 ml/d)
Study: 21431329
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of 200 mg mifepristone orally and 400 μg misoprostol vaginally
Study: 21431329
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 200 mg mifepristone orally and 400 μg misoprostol vaginally at 24-h interval
Study: 21431329
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of 200 mg mifepristone and 400 μg misoprostol
Study: 21431329
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 200 mg mifepristone and 400 μg misoprostol at 24-h interval
Study: 27037432
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided corticosteroid injection (40 mg triamcinolone acetonide and 2 ml 1% lignocaine)
Study: 27037432
Drug: Non-ultrasound guided
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ultrasound guided corticosteroid injection (40 mg triamcinolone acetonide and 2 ml 1% lignocaine)
Study: 25158081
Drug: NRT patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT patches (15 mg per 16 hours) for 8 weeks
Study: 20346057
Drug: Dextromethorphan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (30 or 45 mg)
Study: 19015469
Drug: Alvimopan, 12
Normalized name: Alvimopan, 12 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvimopan, 12 mg, administered orally 30 to 90 minutes preoperatively and twice daily postoperatively
Study: 12444212
Drug: Chlorthalidone and
Normalized name: Chlorthalidone and clonidine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone and Amiloride combination
Study: 9660361
Drug: Sequential initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sequential initiation of zidovudine and lamivudine
Study: 9660361
Drug: Sequential initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sequential initiation of indinavir
Study: 8620678
Drug: Zileuton 800mg
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zileuton 800mg administered twice daily from day 4 to day 8
Study: 8620678
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily from day 4 to day 8
Study: 779756
Drug: Marijuana smoking
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana smoking (0.739 g)
Study: 779756
Drug: Placebo smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo smoking (0.739 g)
Study: 23647307
Drug: IWT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IWT plus post-exercise macronutrient supplementation (7.6 g protein, 32.5 g carbohydrate, and 4.4 g fat)
Study: 17097995
Drug: Two bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two bolus doses of daclizumab (1 mg/kg) on days 1 and 14 posttransplantation
Study: 17097995
Drug: Five bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five bolus doses of daclizumab (1 mg/kg) every 14 days
Study: 17097995
Drug: Two bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two bolus doses of daclizumab
Study: 65273
Drug: 0.7 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg/kg delta9‐tetrahydrocannabinol (THC)
Study: 65273
Drug: 1.0 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml/kg 95% ethanol
Study: 24385118
Drug: Topical cosmetic
Normalized name: Botox Cosmetic
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cosmetic formulation containing N-acetyl tyrosinamide